Abstract:Objective: To summarize and analyze the postoperative short-term complications of laparoscope-assisted transanal total mesorectal excision (taTME) for rectal cancer patients after neoadjuvant therapy. Methods: A prospectively established database on taTME patients at Peking University Cancer Hospital was screened with the following conditions: data retrieval from June 2016 to August 2018, pathologically confirmed adenocarcinoma, receiving preoperative neoadjuvant chemoradiotherapy or chemotherapy. The transabdominal procedure and the transanal procedure were performed simultaneously in the taTME operation. Occurrence of complications during perioperative period (within postoperative 3 months) in these patients, especially anastomosis-related complications and their management were analyzed. The relevant complications were recorded according to the Clavien-Dindo (CD) grading criteria. The severity of anastomotic leakage and anastomotic stenosis was evaluated according to criteria developed by the International Rectal Cancer Research Group. Results: A total of 29 patients were enrolled in this study. In the 29 patients, 25 (86.2%) were male and 4 (13.8%) were female, the median age was 60 (range, 30 to 72) years, the median body mass index was 25.8 (range, 19.8 to 36.4) kg/m2, the median distance from the tumor to anal verge was 4 (range, 2 to 8) cm. All the patients completed laparoscope-assisted taTME operations successfully without conversion to laparotomy, intra-operative severe complication or death. The median operation time was 300 (range, 198 to 405) minutes, and the median intra-operative blood loss was 100 (range, 50 to 200) ml. All the TME specimens were complete according to the Nagtegaal standard. All the patients underwent prophylactic ileostomy. Hartmann procedure was performed in one case due to poor blood supply in the proximal bowel without the possibility of anastomosis. Anal sphincter preservation rate was 96.6% (28/29). The median postoperative exhaust time was 2 (range, 1 to 10) days, and the median postoperative hospital stay was 9 (range, 7 to 24) days. Fifteen patients (51.7%) had postoperative complications, among which serious complication (CD grade IIIb and above) accounted for 6.9% (2/29). No perioperative death was observed. Five patients (17.2%) presented anastomosis-related complications, including 2 cases of grade C anastomotic leakage due to anastomotic rupture, who underwent abdominal perineal resection 1 month after operation; 2 cases of grade B anastomotic leakage, who improved after conservative treatment; 1 case of grade A anastomotic stenosis, who improved with anal expansion 1 month after operation. The incidence of postoperative infection was 24.1% (7/29), including 6 cases of pelvic infection and 1 case of trocar site infection, all of which were CD grade II. One case had incomplete intestinal obstruction (CD grade II); 1 case had gastroplegia; 1 case had abdominal trocar hernia. All the patients were followed up for a median of 12.0 (range, 3.9 to 29.9) months. Seven cases did not undergo ileal stoma closure. The anal sphincter preservation rate was 75.9% (22/29). Conclusion: Pelvic infection and anastomosis-related complications are common after laparoscope-assisted taTME surgery for rectal cancer patients following neoadjuvant chemoradiotherapy, which require active management and appropriate treatment.

Incidence and Risk Factors of Surgical Complications and Anastomotic Leakage after Transanal Total Mesorectal Excision for Middle and Low Rectal Cancer.

[Short-term complications after transanal total mesorectal excision for mid-low rectal cancer]

The application of laparoscopic total mesorectal excision with preservation of anal sphincter for rectal cancer

[Postoperative short-term complications of laparoscope-assisted transanal total mesorectal excision for rectal cancer after neoadjuvant therapy and their management: a single center report]

[Incidence and Risk Factors of Anastomotic Leak after Transanal Total Mesorectal Excision in China: a Retrospective Analysis Based on National Database].

[Risk Factors of Anastomotic Leakage in the Procedures of Trans-Abdominal and Transanal Total Mesorectal Excision for Rectal Cancer].

Risk factors analysis on anastomotic leakage after total mesorectal excision for rectal carcinoma

Incidence and Risk Factors for Low Anterior Resection Syndrome following Trans-Anal Total Mesorectal Excision

Risk Factors Analysis and Strategy for Anastomotic Leakage after Total Mesorectal Excision

Multicenter Investigation of Bowel Evacuation Function after Transanal Total Mesorectal Excision for Mid-Low Rectal Cancer

Transanal Total Mesorectal Excision for Rectal Cancer: a Multicentric Cohort Study.

[Efficacy of Transanal Hand-Sewn Reinforcement in Low Rectal Stapled Anastomosis in Preventing Anastomotic Leak after Transanal Total Mesorectal Excision].

Morbidity, Mortality, and Pathologic Outcomes of Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer Short-term Outcomes From a Multicenter Randomized Controlled Trial

Evaluation of laparoscopic-assisted transanal total mesorectal excision (Ta-TME) for locally advanced distal rectal cancer in men with difficult pelvic conditions after neoadjuvant chemoradiation therapy

Incidence of Postoperative Anastomotic Leakage of Laparoscopic and Open Total Mesorectal Excision for Rectal Cancer:Meta-analysis

Transanal total mesorectal excision: Understanding indications, managing complications, and effective prevention methods

Transanal total mesorectal excision (taTME) for cancer located in the lower rectum: short- and mid-term results

Transanal total mesorectal excision in re-operation for anastomosis recurrence rectal cancer

Laparoscopic total mesorectal excision versus transanal total mesorectal excision for mid and low rectal cancer: A systematic review and meta-analysis

Low anterior resection syndrome after transanal total mesorectal excision in rectal cancer

A systematic review and meta‐analysis of oncological outcomes with transanal total mesorectal excision for rectal cancer